Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Operating Leases: 2022-2024

Historic Operating Leases for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Dec 2024 value amounting to $463,000.

  • Amylyx Pharmaceuticals' Operating Leases fell 2.86% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 2.86%. This contributed to the annual value of $463,000 for FY2024, which is 76.62% down from last year.
  • Amylyx Pharmaceuticals' Operating Leases amounted to $463,000 in FY2024, which was down 76.62% from $2.0 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Operating Leases' 5-year high stood at $4.2 million during FY2022, with a 5-year trough of $463,000 in FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Operating Leases value was $2.0 million (recorded in 2023), while the average stood at $2.2 million.
  • Data for Amylyx Pharmaceuticals' Operating Leases shows a maximum YoY tumbled of 76.62% (in 2024) over the last 5 years.
  • Over the past 3 years, Amylyx Pharmaceuticals' Operating Leases (Yearly) stood at $4.2 million in 2022, then tumbled by 53.27% to $2.0 million in 2023, then slumped by 76.62% to $463,000 in 2024.